Inhibrx/INBX

$38.06

1.06%
-
1D1W1MYTD1YMAX

About Inhibrx

Inhibrx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of biologic therapeutic candidates in oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, INBRX-109, INBRX-105 and INBRX-106. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD) and acute Graft-versus -host-disease (aGvHD). INBRX-109 is an engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand or TRAIL receptor 2. INBRX-105 is a conditional tetravelent PD-L1 targeted 4-1BB agonist that is being investigated as a single agent and in combination with Keytruda in patients with locally advanced or metastatic solid tumors.
Ticker
INBX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Mark Lappe
Employees
132
Headquarters
La jolla, United States

Inhibrx Metrics

BasicAdvanced
$1.79B
Market cap
-
P/E ratio
-$4.24
EPS
2.99
Beta
-
Dividend rate

What the Analysts think about Inhibrx

Analyst Ratings

Majority rating from 3 analysts.
Hold

Price Targets

Average projection from 3 analysts.
14.16% downside
High $36.00
Low $27.00
$38.06
Current price
$32.67
Average price target

Inhibrx Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-51,700% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$100K
∞%
Net income
$-51.7M
10%
Profit margin
-51,700%
-∞%

Inhibrx Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 8.91%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.95
-$1.12
-$1.08
-$1.10
-
Expected
-$0.79
-$0.84
-$1.03
-$1.01
-$1.04
Surprise
20.56%
32.7%
4.55%
8.91%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Inhibrx stock

Buy or sell Inhibrx stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing